LONDON (Alliance News) - C4X Discovery Holdings PLC said Thursday that it has entered into a drug discovery partnership with GTN Ltd, a company using artificial intelligence to discover new drug-like molecules.
Under the agreement, the companies will aim to identify novel small molecules. C4X Discovery - using its analysis platform Conformetrix - will provide GTN with molecular descriptors for use in its in-silico discovery platform.
"Leveraging the clear synergies that exist between our Conformetrix platform and GTN's in-silico discovery technology, we aim to solve the representation problem and enable pioneering research into unexplored chemical space against a commercially attractive neurodegeneration target. We are looking forward to seeing the results of this project," said Craig Fox, C4X Discovery's chief science officer.
Shares in C4X Discovery were trading 3.8% higher at 80.95 pence each.
